Literature DB >> 19300460

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules.

David Marsolais1, Hugh Rosen.   

Abstract

Biological barriers regulate the passage of cells, pathogens, fluids, nutrients, ions and signalling molecules between anatomical compartments during homeostasis and disease. Yet strategies that allow for reversible therapeutic modulation of these barriers are still in their infancy. The enhancement or protection of natural barriers is desirable in conditions such as acute respiratory distress syndrome or ischaemia-reperfusion injuries, whereas a temporary disruption could facilitate the penetration of drugs across such barriers. This Review discusses the role of sphingosine-1-phosphate receptors in the regulation and protection of biological barriers, and the potential of therapeutic strategies that target this receptor family.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300460      PMCID: PMC4455967          DOI: 10.1038/nrd2356

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  116 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

Review 2.  Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness.

Authors:  Bodo Levkau
Journal:  Circ Res       Date:  2008-08-01       Impact factor: 17.367

Review 3.  Tipping the gatekeeper: S1P regulation of endothelial barrier function.

Authors:  Hugh Rosen; M Germana Sanna; Stuart M Cahalan; Pedro J Gonzalez-Cabrera
Journal:  Trends Immunol       Date:  2007-02-05       Impact factor: 16.687

4.  Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury.

Authors:  James A Frank; Charlie M Wray; Danny F McAuley; Reto Schwendener; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-07-28       Impact factor: 5.464

Review 5.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

6.  Sphingosine 1-phosphate analogs as receptor antagonists.

Authors:  Michael D Davis; Jeremy J Clemens; Timothy L Macdonald; Kevin R Lynch
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

7.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.

Authors:  Michael D Prados; S Clifford Schold; Howard A Fine; Kurt Jaeckle; Fred Hochberg; Laszlo Mechtler; Michael R Fetell; Surasak Phuphanich; Lynn Feun; Todd J Janus; Kathleen Ford; William Graney
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

8.  Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration.

Authors:  T S Panetti; J Nowlen; D F Mosher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

9.  Deafness and stria vascularis defects in S1P2 receptor-null mice.

Authors:  Mari Kono; Inna A Belyantseva; Athanasia Skoura; Gregory I Frolenkov; Matthew F Starost; Jennifer L Dreier; Darcy Lidington; Steffen-Sebastian Bolz; Thomas B Friedman; Timothy Hla; Richard L Proia
Journal:  J Biol Chem       Date:  2007-02-06       Impact factor: 5.157

Review 10.  Treatment of acute renal failure.

Authors:  R A Star
Journal:  Kidney Int       Date:  1998-12       Impact factor: 10.612

View more
  65 in total

1.  Differential modulation of S1PR(1-5) and specific activities of SphK and nSMase in pulmonary and cerebral tissues of rats exposed to hypobaric hypoxia.

Authors:  Sonam Chawla; Shweta Saxena
Journal:  Lipids       Date:  2014-11-16       Impact factor: 1.880

2.  Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.

Authors:  Perry C Kennedy; Ran Zhu; Tao Huang; Jose L Tomsig; Thomas P Mathews; Marion David; Olivier Peyruchaud; Timothy L Macdonald; Kevin R Lynch
Journal:  J Pharmacol Exp Ther       Date:  2011-06-01       Impact factor: 4.030

Review 3.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 4.  Sphingosine-1-phosphate and immune regulation: trafficking and beyond.

Authors:  Hongbo Chi
Journal:  Trends Pharmacol Sci       Date:  2010-12-14       Impact factor: 14.819

5.  Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury.

Authors:  Xiaoguang Sun; Patrick A Singleton; Eleftheria Letsiou; Jing Zhao; Patrick Belvitch; Saad Sammani; Eddie T Chiang; Liliana Moreno-Vinasco; Michael S Wade; Tong Zhou; Bin Liu; Ioannis Parastatidis; Leonor Thomson; Harry Ischiropoulos; Viswanathan Natarajan; Jeffrey R Jacobson; Roberto F Machado; Steven M Dudek; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-05       Impact factor: 6.914

Review 6.  Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.

Authors:  Philip R Mayeux; Lee Ann MacMillan-Crow
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

7.  Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.

Authors:  Bin Ma; Kevin M Guckian; Edward Yin-Shiang Lin; Wen-Cherng Lee; Daniel Scott; Gnanasambandam Kumaravel; Timothy L Macdonald; Kevin R Lynch; Cheryl Black; Sowmya Chollate; Kyungmin Hahm; Gregg Hetu; Ping Jin; Yi Luo; Ellen Rohde; Anthony Rossomando; Robert Scannevin; Joy Wang; Chunhua Yang
Journal:  Bioorg Med Chem Lett       Date:  2010-02-06       Impact factor: 2.823

Review 8.  A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.

Authors:  Kenechukwu O Chudy-Onwugaje; Kaci E Christian; Francis A Farraye; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

9.  Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.

Authors:  Alice Laroni; Davide Brogi; Vincenzo Brescia Morra; Leonello Guidi; Carlo Pozzilli; Giancarlo Comi; Alessandra Lugaresi; Renato Turrini; Debora Raimondi; Antonio Uccelli; Giovanni Luigi Mancardi
Journal:  Neurol Sci       Date:  2016-10-18       Impact factor: 3.307

10.  Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.

Authors:  Kevin B Walsh; David Marsolais; Megan J Welch; Hugh Rosen; Michael B A Oldstone
Journal:  Virology       Date:  2009-12-03       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.